Walden Biosciences

Walden Biosciences is a private, preclinical to clinical-stage biotech dedicated to creating direct kidney-targeted therapies for a range of kidney diseases. The company is advancing a pipeline of novel candidates, with its lead asset, WAL0921, progressing toward Phase 2 trials for rare kidney diseases as of late 2025. Operating from the biotech hub of Cambridge, Walden is positioning itself to address significant unmet medical needs in nephrology through a focused therapeutic approach.

Platform for developing novel therapies (antibodies, biologics, small molecules) that directly target the kidney to modify disease progression.

The kidney disease therapeutic landscape is becoming increasingly competitive, with large pharma (e.g., AstraZeneca, Bayer, Novo Nordisk) and biotechs pursuing various mechanisms. Walden's niche is its focus on direct kidney-targeting therapies, but it will compete against companies with greater resources and later-stage pipelines in overlapping indications.